A biotech startup based in Poland is working on a technology which it claims could revolutionise the way CBD products are absorbed.
Low absorption of CBD products in the body is a concern for manufacturers and consumers alike, as the level of absorption ultimately determines the efficacy of these preparations and their popularity.
Healthcann, which was founded by three PhD students from the Department of Biotechnology and Food Science at Wroclaw University of Life Sciences, has developed a new technology which aims to improve the bioavailability of CBD.
The proposed technology AdvanDrop is said to solve the problem of slow-acting and low bioavailability of active substances that do not dissolve in water, including cannabidiol (CBD).
The therapeutic potential of many health and wellness supplements, including CBD, is largely untapped due to its very low bioavailability in the body after oral intake.
Healthcann cites statistics which say around a third of therapeutic and health-promoting substances that are currently available on the market could be characterised by low absorption.
Grzegorz Kielbowicz PhD, CEO of Healthcann, says: “The research we are conducting is about to start a new era in the area of prevention and healthcare. Our proposed technology AdvanDrop is expected to help treat chronic diseases more effectively, for example by improving the absorption of health substances.
“The level of absorption is today an essential factor in determining the success and effectiveness of a drug or supplement on the mass market. The low level of absorption of many popular dietary supplements makes their consumption of negligible importance for human health.”
How does the technology work?
In a statement, the company explained how this new technology works.
A significant increase in the absorption of drugs and supplements into the body can be achieved through the use of lipid carrier technology, say the experts behind AdvanDrop.
This will enable the active substances of a medicine to be encapsulated in small vesicles (nanoparticles). The small size of these nanoparticles will facilitate and accelerate the penetration of the medicinal substance into the human digestive system.
AdvanDrop causes the absorption of the compounds to start as early as in the mouth, from where they reach the jugular vein and are distributed throughout the body. Healthcann claims this enables the effects to be felt in just five to 10 minutes.
The remainder of AdvanDrop passes into the oesophagus and reaches the stomach, where it protects the CBD from degradation and facilitates delivery to the duodenum and further parts of the small intestine. In the small intestine, AdvanDrop mimics the natural process of fat digestion to maximise absorption of the compounds.
Dr Kielbowicz says the technology has been shown to increase CBD absorption by 200% and the levels of CBD in the blood by 26 times in just five minutes.
“The essence of our technology is the ability to dissolve compounds that do not dissolve in water. As a result, they can be taken in a convenient and discreet form, for example, in combination with a favourite drink or as lozenges,” he explained.
“What’s more, AdvanDrop makes these compounds work faster and more effectively. In the case of CBD, we have demonstrated a 200% higher absorption rate and a 26 times higher concentration of this substance in the blood just five minutes after ingestion compared to standard CBD oils.
Dr Kielbowicz added: “We have also used AdvanDrop to create products that provide vitamins A, D, E and K. We believe that the absorption of these valuable compounds for human health has now gone to another level.”
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure